| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg | |||
| Other Sizes |
| Targets |
Taribavirin targets inosine monophosphate dehydrogenase (IMPDH) and RNA-dependent RNA polymerase (RdRp). As a prodrug, it is converted to ribavirin in the liver by adenosine deaminase. Ribavirin inhibits IMPDH, affecting viral RNA replication. It also directly suppresses HCV replication by inhibiting RdRp.
|
|---|---|
| ln Vitro |
Taribavirin hydrochloride (0-2 μM; 24 hours) has been shown to strongly promote MCF-7 cell death, with an IC50 of 0.756 μM in MCF-7 cells [1].
In vitro, Taribavirin hydrochloride shows antiviral activity by inhibiting viral RNA synthesis and replication. As a nucleoside analog, it is a precursor to ribavirin in the liver. It enhances the host's T-cell-mediated antiviral immunity by initiating the transformation of the T-cell phenotype from type 2 to type 1. |
| ln Vivo |
In vivo, Taribavirin is an oral prodrug of ribavirin, primarily developed for the treatment of chronic hepatitis C virus (HCV) infections. It is designed to concentrate in the liver to target HCV-infected hepatocytes, while minimizing distribution within red blood cells. It has improved pharmacokinetic properties and reduced toxicity compared to ribavirin.
|
| Enzyme Assay |
In vitro antiviral assays for Taribavirin involve measuring inhibition of viral replication. Cells infected with HCV or influenza virus are treated with varying concentrations of Taribavirin. Viral RNA levels are measured by qRT-PCR. IC50 values are calculated from concentration-response curves. IMPDH inhibition can be assessed by measuring enzyme activity in cell lysates.
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: MCF-7 Cell Tested Concentrations: 0 μM, 0.1 μM, 1 μM, 2 μM Incubation Duration: 24 hrs (hours) Experimental Results: MCF-7 cell growth diminished. For in vitro cell-based assays, hepatocytes or other susceptible cells are infected with virus and treated with Taribavirin at various concentrations. Viral replication is assessed by measuring viral RNA or protein levels. Cell viability is assessed using MTT or similar assays. |
| Animal Protocol |
In vivo animal studies for Taribavirin would typically use mouse models of viral infection. The compound is administered orally at doses determined from pharmacokinetic studies. Viral load is measured in tissues. Liver targeting and distribution are assessed. Specific protocols are not extensively documented in the available literature.
|
| ADME/Pharmacokinetics |
Taribavirin hydrochloride (CAS 40372-00-7) has a molecular formula of C8H13N5O4·HCl and a molecular weight of 279.68. It is a hydrochloride salt. It is an orally active prodrug. It is soluble in DMSO. Detailed pharmacokinetic parameters are not extensively characterized.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for Taribavirin are not extensively provided. Compared to ribavirin, it has reduced toxicity. As a nucleoside analog, it would be expected to have a safety profile related to nucleic acid metabolism. The compound is for research use only. Standard toxicology assessments would be required for therapeutic development.
|
| References | |
| Additional Infomation |
Taribavirin hydrochloride is the hydrochloride form of ribavirin, an oral prodrug of ribavirin. Ribavirin is a synthetic nucleoside analog with a structure similar to furanylribose, and it is active against a variety of viruses, especially hepatitis C virus and influenza virus. Taribavirin is converted to ribavirin in the body, which can be incorporated into viral nucleic acid, thereby inhibiting viral RNA synthesis, inducing viral genome mutations, and suppressing normal viral replication.
Taribavirin hydrochloride, also known as Viramidine, is an oral prodrug of ribavirin, primarily developed for the treatment of chronic hepatitis C virus (HCV) infections. It is converted into ribavirin, which inhibits viral RNA synthesis and replication. It has improved pharmacokinetic properties and reduced toxicity compared to ribavirin. No approved therapeutic status is reported. |
| Molecular Formula |
C8H14CLN5O4
|
|---|---|
| Molecular Weight |
279.681
|
| Exact Mass |
279.073
|
| CAS # |
40372-00-7
|
| Related CAS # |
Taribavirin;119567-79-2
|
| PubChem CID |
451447
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
18
|
| Complexity |
304
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1=NC(=NN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=N)N.Cl
|
| InChi Key |
PIGYMBULXKLTCJ-UHSSARMYSA-N
|
| InChi Code |
InChI=1S/C8H13N5O4.ClH/c9-6(10)7-11-2-13(12-7)8-5(16)4(15)3(1-14)17-8/h2-5,8,14-16H,1H2,(H3,9,10)1H/t3-,4-,5-,8-/m1./s1
|
| Chemical Name |
1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1H-1,2,4-triazole-3-carboximidamide hydrochloride
|
| Synonyms |
AVS-206, ICN3142, KD-024,AVS 206, ICN 3142, KD 024,AVS206, ICN-3142, KD024, Ribamidine, Viramidine, Taribavirin HCl
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~357.55 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5755 mL | 17.8776 mL | 35.7551 mL | |
| 5 mM | 0.7151 mL | 3.5755 mL | 7.1510 mL | |
| 10 mM | 0.3576 mL | 1.7878 mL | 3.5755 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
